Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation

Clinical and Experimental Dermatology

Volumn 38, Issue 1, 2013, Pages 44-46

  Palanivel, Janani A ^a   MacBeth, A E ^a   Levell, N J ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; JANUS KINASE 2; STAT PROTEIN;

ADULT; ARTICLE; CASE REPORT; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LEG ULCER; MALE; PHLEBOTOMY; PRESCRIPTION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SIGNAL TRANSDUCTION; SKIN BIOPSY; ULCER HEALING; VASCULITIS;

HUMANS; JANUS KINASE 2; LEG; MALE; MIDDLE AGED; MUTATION; PYODERMA GANGRENOSUM;

EID: 84872833925     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2012.04375.x     Document Type: Article

References (6)

1. Rawlings JS, Rosler KM, Harrison AD,. The JAK/STAT signalling pathway. J Cell Sci 2004; 117: 1281-3.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
3. Ross HJ, Moy LA, Kaplan R, Figlin RA,. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991; 68: 441-3.
4. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation. Single nucleotide polymorphisms in the STAT-JAK pathway: susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutal Res 2010; 690: 108-15.
5. Walker JG, Smith MD,. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005; 32: 1650-3.
6. Pardanani A, Tefferi A,. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011; 18: 105-10.